Hunan Provincial Key Laboratory for Synthetic Biology of Traditional Chinese Medicine, School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, 418000 Hunan, China.
Chenzhou No.1 People's Hospital, Chenzhou, 423000 Hunan, China.
Biomed Res Int. 2020 Aug 5;2020:2743060. doi: 10.1155/2020/2743060. eCollection 2020.
This study constructed a model for the early diagnosis of gastric cancer by comparing the serum peptides profiles of patients with advanced gastric cancer and healthy people. And that model may be the potential to be applied for the efficacy evaluation and recurrence monitoring in gastric cancer.
Serums of 30 healthy people and 30 advanced gastric cancer patients were matched by age and gender were collected. The serum peptide spectrum was obtained by MB-WCX concentration and MALDI-TOF MS analysis. Based on the analysis of the efficiency of differential peptides in the diagnosis of gastric cancer, we first established a model for the diagnosis of gastric cancer based on differential peptides and then carried out external verification. The diagnostic reliability of this model was further tested by compared with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
In this present study, we found the expression of two peptide peaks with a molecular weight of 2863 Da and 2953 Da were significantly increased in gastric cancer serum, while the expression of two peptide peaks with a molecular weight of 1945 Da and 2082 Da were significantly decreased. Depending on the characteristics of peptide expression, we constructed a diagnostic model, we compared the sensitivity and specificity of the model established by 2953 Da/1945 Da, and found this model is significantly higher than CEA and CA19-9.
There were some differences in serum peptides profiles between patients with advanced gastric cancer and healthy people. The serum peptide diagnostic models based on 2953 Da and 1945 Da have high diagnostic efficiency for advanced gastric cancer. Our result indicated that this model was well worth further validation for clinical diagnosis.
本研究通过比较晚期胃癌患者与健康人群的血清肽谱，构建了一种用于早期胃癌诊断的模型。该模型可能有潜力用于胃癌的疗效评价和复发监测。
收集了 30 名健康人和 30 名晚期胃癌患者的年龄和性别相匹配的血清。采用 MB-WCX 浓缩和 MALDI-TOF MS 分析获得血清肽谱。基于分析差异肽在胃癌诊断中的效率，我们首先建立了基于差异肽的胃癌诊断模型，然后进行了外部验证。通过与癌胚抗原（CEA）和糖类抗原 19-9（CA19-9）的比较，进一步测试了该模型的诊断可靠性。
本研究发现，胃癌血清中两种分子量为 2863 Da 和 2953 Da 的肽峰表达显著升高，而两种分子量为 1945 Da 和 2082 Da 的肽峰表达显著降低。根据肽表达的特点，我们构建了一个诊断模型，比较了由 2953 Da/1945 Da 建立的模型的灵敏度和特异性，发现该模型明显高于 CEA 和 CA19-9。
晚期胃癌患者与健康人群的血清肽谱存在差异。基于 2953 Da 和 1945 Da 的血清肽诊断模型对晚期胃癌具有较高的诊断效率。我们的结果表明，该模型非常值得进一步验证用于临床诊断。
